Sunday, October 20, 2019
News
NEWS HOME
Ľ
PRESS RELEASES

Solasia Announces Patient Registration Reached Target Number of Cases for Darinaparsin Phase 2 Pivotal Study for T-Cell Lymphoma
  SocialTwist Tell-a-Friend  
   


Date: 17-09-2019 5:10PM
Source: Solasia Pharma K.K.
Category: General, Science & Research, Healthcare & Biotechnology, Pharmaceutical
Location: TOKYO, Japan

Business Wire India

Solasia Pharma K.K. (TSE:4597, Headquarters: Tokyo, President & CEO: Yoshihiro Arai, hereinafter “Solasia”), a specialty pharmaceutical company based in Asia, today announced that patient registration reached the target number of cases for the darinaparsin Phase 2 study.

The Phase 2 study is being conducted as a multinational, multicentre, single-arm, open-label, non-randomized study to evaluate the efficacy and safety of darinaparsin monotherapy in relapsed or refractory patients with peripheral T-cell lymphoma (hereinafter “PTCL”) in Japan, South Korea, Taiwan and Hong Kong. Patients would receive maximum 6 cycles of darinaparsin, and the efficacy would be measured with tumor response as primary outcome measure.

This study is a pivotal (final) study for PTCL based on prior consultation with the authority. At present, Solasia expects to announce the study results in 2020.

Solasia holds an exclusive worldwide license to develop and commercialize darinaparsin. For Japan market, Solasia has already entered into an exclusive license agreement with Meiji Seika Pharma Co., Ltd., for the commercialization of darinaparsin, and for Latin America, with HB Human BioScience SAS. Going forward, Solasia will actively seek licensing partners outside of Asia.

Through the active development of darinaparsin, Solasia will continue to strive for providing new treatment option for PTCL patients. Furthermore, Solasia will continue to pursuit the possibility for developing other indications in cancer field following PTCL.

About darinaparsin
Darinaparsin is a novel mitochondrial-targeted agent (organoarsenic) being developed for the treatment of various hematologic and solid cancers. In a US Phase 2 study, darinaparsin demonstrated evidence of clinical activity in lymphoma, in particular PTCL. Furthermore, the Phase 1 study done in US, and the Pan-Asian Phase 1 study both demonstrated positive efficacy and safety. Darinaparsin has been granted orphan drug designation in US and EU. For more information, please see at https://www.solasia.co.jp/en/pipeline/sp-02.html

About Solasia
Solasia is a specialty pharmaceutical company based in Asia, with a mission of "Better Medicine for a Brighter Tomorrow". In order to address the unmet medical needs within the oncology area, we develop innovative medicines to contribute to the patient's healthy living and to provide treatment options for the healthcare providers. For more information, please visit https://www.solasia.co.jp/en/



CONTACTS :

Solasia Pharma K.K.
Rie Toyoda, Public Relations and Investor Relations,
Tel. +81 3 5843 8049
info@solasia.co.jp

More Press Releases

New Research Reveals Updated Patient Preferences on Digital Health Technology

The Federal Councilor, Simonetta Sommaruga of Switzerland, Department of Environment, Transport, Energy and Communications, Visits the ABB Ability Innovation Center in Bengaluru

RIMES Opens New Operational Hub in Manila

Bina Modi Conferred With Ph.D., Honoris Causa by Dr. K.N. Modi University

Dive In: The Festival for Diversity and Inclusion in Insurance

BUSINESS ENGINEER Enables 4x Ecommerce Business Growth for KEYA Foods on Completion of Phase-I Order Fulfillment Project

Professor Michael E. Porter Addresses the Gathering at Porter Prize 2019

Schlumberger Announces Third-Quarter 2019 Results

CDIB Capital Group Appoints Mr. Angelo J.Y. Koo as Chairman to Lead Global Asset Management Business

L&T Technology Services Continues Double-Digit Revenue Growth in Q2FY20

VARU - the 5th Tropical Resort by Atmosphere Hotels & Resorts Launched in the North-West of Maldives on 17th October 2019

Kalpataru Launches Integrated Mixed Use Township Kalpataru Parkcity in Thane

#JustEMI to Fulfil All Your Aspirations This Diwali and Shop Without Compromise With Bajaj Finserv

Frost & Sullivanís GIL 2019: India Aimed to Uncover the Next Wave of Sustainable Top-Line Revenue Growth, Customer Value, and Future of the Connected World

The Hero Campus Challenge Returns to Nurture the Business Leaders of Tomorrow

Vakilsearch Signs MoU With the Largest Dutch Legal-Tech Company

Make Your Diwali Thrilling with RummyBaazi.com

The 46th Tokyo Motor Show 2019: Events and Programs News Update

Pioneer Cement of UAE to Develop US$200 Million Greenfield Cement Project in Georgia

FlowerAura Launches Profile Picture Worthy Bhai Dooj Gifts for 2019

Secure Your New Smartphone With Mobile Screen Insurance From Bajaj Finserv

Mavenir Confirmed as Global Leader in NFV-based IMS Solutions

Andersen Global Expands in India With Membership of Nangia Andersen LLP

Lookout App Defense Penetrates Global Markets With New Customers and Strategic Partnerships, Helping Customers Prevent Data Compromise in Mobile Apps

PTC Launches Global Event Series with FT Live to Help Industrial Enterprises Embrace Digital Transformation

Historic Conrad Hilton Bel-Air Estate Hits Market for $225 Million

 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
INDIA WORLD ASIA
Pune: Country made pistols seized, one d...
Maharashtra: Rs 142 crores, 975 illegal ...
UP: BSF jawan killed in firing by Bangla...
Ahead of polls, IT seizes Rs 29 cr cash ...
Mirchi deals: ED raids 14 DHFL, Sunblink...
Plan to kill Kamlesh Tiwari hatched 2 mo...
More...    
 
 Top Stories
Isla Fisher goes to market without ... 
Indian athletes L Suriya, Srinu Bug... 
Train services affected between CSM... 
UK MPs vote for amendment to force ... 
Ranveer takes time management tips ... 
Five killed in twin attacks in Burk... 
ICC approves Aahan Achar as replace... 
Jennifer Lawrence ties the knot wit...